The global Neuropathic Pain Therapeutics market garnered revenue around USD 5.9 Billion in 2019 and projected to reach USD 10.3 Billion in 2027, with at a compound annual growth rate (CAGR) 5.1% throughout the estimate period from 2020 to 2027. Neuropathic pain can occur in different indications including diabetic neuropathy, post-herpetic neuralgia, cancer-related pain, spinal cord injury, and others. Drug classes used to treat neuropathic pain are anticonvulsants, antidepressants, NSAIDs, opioids, steroids, and others. Moreover, rise in prevalence of neuropathic pain and increase in geriatric population leading to surge in cases of nerve pain among the population across the globe are boosting the growth of the global market. North America dominated the global neuropathic pain therapeutics market in 2019 and the trend is anticipated to continue during the forecast period. Rise in adoption of neuropathic pain therapeutics for treatment and increase in number of clinical trials for the development of these products for different disorders fuel the growth of the market in the region.
Asia Pacific is expected to be a highly lucrative market for neuropathic pain treatments during the forecast period, owing to the increase in geriatric population, rise in awareness about neuropathic conditions, and surge in focus of leading players toward targeting developing countries such as India and China.
This research report encompasses precise assessment of the market with the help of comprehensive qualitative insights and supportable prognoses regarding market size, consumption and production. The projections presented in the report have been derived using proven research methodologies and assumptions. It does so by means of comprehensive qualitative insights, historical statistics, and verifiable predictions about market revenue and sales.
The rapidly budding threat owed to the eruption of COVID-19 is impacting lives, communities, businesses, and industries across the globe. With businesses shuttered, flights grounded, COVID-19 is about to affect the global economy in different ways such as by directly upsetting production and demand, by generating supply chain disruption, and by its financial impact on firms and financial markets. Therefore, this report covers COVID-19 outbreak impact analysis on the Neuropathic Pain Therapeutics market under the research study. The market estimates offered in the report are the outcome of in-depth extensive secondary research, primary interviews and in-house professional assessments. These market evaluations have been measured by reviewing the impact of numerous social, political and economic factors coupled with recent market dynamics affecting the Neuropathic Pain Therapeutics market growth.
The global Neuropathic Pain Therapeutics market is characterized by the presence of numerous small as well as medium scale companies. These players are largely focused towards forward integration via raw material production, product manufacturing, and distribution across various industry verticals. The report recognizes numerous crucial manufacturers of the market. This research study aids to comprehend the strategies and associations that companies are converging to survive in this competitive marketplace. This report assists in understanding footprints of the manufacturers with the help of their global revenue, production, capacity and average selling price analysis for period 2016-2027.
Major manufacturers analysed under this study comprises:
the global market include Pfizer, Novartis AG, AstraZeneca, GlaxoSmithKline, Eli Lilly and Company, Mallinckrodt Pharmaceuticals, Johnson & Johnson, Abbott, Endo Pharmaceuticals, Inc., Teva Pharmaceutical Industries Limited, and Merck & Co., Inc.
This report delivers market breakdown and its revenue, consumption, production analysis and projections by categorizing it depending on parameters such as type, application/end-user, and region. This research report delivers the analysis and prognosis of revenue, production, price, market share and growth trend for different products such as:
Global Neuropathic Pain Therapeutics Market: Segmentation
- Neuropathic Pain Therapeutics Market, by Drug Class
- Anticonvulsants
- Antidepressants
- Tricyclic Antidepressants
- Serotonin-norepinephrine Reuptake Inhibitors (SNRIs)
- NSAIDs
- Opioids
- Steroids
- Others
- Neuropathic Pain Therapeutics Market, by Indication
- Diabetic Neuropathy
- Post-herpetic Neuralgia
- Cancer-related Pain
- Spinal Cord Injury
- Others
- Neuropathic Pain Therapeutics Market, by Route of Administration
- Neuropathic Pain Therapeutics Market, by Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
Regional Analysis and Forecast
Further, this research study analyses market size, production, consumption and its advancement trends at global, regional, and country level for period 2016 to 2027 and covers following region in its scope:
- North America
- Europe
- Germany
- United Kingdom
- Italy
- France
- Rest of EU
- Asia Pacific
- China
- India
- Japan
- Southeast Asia
- Rest of APAC
- Central & South America
- Brazil
- Argentina
- Rest of Central & South America
- Middle East and Africa
- UAE
- Saudi Arabia
- Rest of MEA
Request Customization
Get a Sample
Get a Sample
Request Customization